Indianapolis researchers are developing technology which could lessen negative side affects during stem cell transplants for cancer patients. general Biotechnology's apparatus pumps bone marrow stem cells through a especially designed tube. The fiber filled tube moderately cleans the Dimethyl Sulfoxide preservative from the bone marrow transplant whiles still maintaining the cell’s efficacy. DMSO is a usually applied preservative which increases the shelf life of cells, but can cause complications with patients when it is injected into their system.
“There has been a demand for this technology as long as frozen bone marrow transplants have been used to treat patients. This project originated through our company’s mission of listening to physicians and specifically developing technologies to meet critical needs,” said Erik J. Woods, Ph.D., president and chief executive officer of General BioTechnology. “Over 30,000 people a year in this country receive this type of procedure, our hope is that our system will help yield better outcomes with fewer complications.”
For more information visit: http://stemcellumbilicalcordblood.com/tag/stem-cell-cancer-treatment/
No comments:
Post a Comment